Id: acc4521
Group: 1sens
Protein: FGFR1
Gene Symbol: FGFR1
Protein Id: P11362
Protein Name: FGFR1_HUMAN
PTM: phosphorylation
Site: Tyr654
Site Sequence: ARDIHHIDYYKKTTNGRLPVK
Disease Category: Cancer
Disease: Breast Cancer
Disease Subtype: ER-positive
Disease Cellline:
Disease Info:
Drug: tamoxifen
Drug Info: Tamoxifen is a selective estrogen receptor modulator commonly used in the treatment of breast cancer.
Effect: inhibit
Effect Info: Obesity leads to increased phosphorylation of FGFR1 and is associated with shortened disease - free survival and cancer - specific survival in patients receiving tamoxifen treatment.
Note:
Score: 5.0
Pubmed(PMID): 30046001
Sentence Index:
Sentence:

Sequence & Structure:

MWSWKCLLFWAVLVTATLCTARPSPTLPEQAQPWGAPVEVESFLVHPGDLLQLRCRLRDDVQSINWLRDGVQLAESNRTRITGEEVEVQDSVPADSGLYACVTSSPSGSDTTYFSVNVSDALPSSEDDDDDDDSSSEEKETDNTKPNRMPVAPYWTSPEKMEKKLHAVPAAKTVKFKCPSSGTPNPTLRWLKNGKEFKPDHRIGGYKVRYATWSIIMDSVVPSDKGNYTCIVENEYGSINHTYQLDVVERSPHRPILQAGLPANKTVALGSNVEFMCKVYSDPQPHIQWLKHIEVNGSKIGPDNLPYVQILKTAGVNTTDKEMEVLHLRNVSFEDAGEYTCLAGNSIGLSHHSAWLTVLEALEERPAVMTSPLYLEIIIYCTGAFLISCMVGSVIVYKMKSGTKKSDFHSQMAVHKLAKSIPLRRQVTVSADSSASMNSGVLLVRPSRLSSSGTPMLAGVSEYELPEDPRWELPRDRLVLGKPLGEGCFGQVVLAEAIGLDKDKPNRVTKVAVKMLKSDATEKDLSDLISEMEMMKMIGKHKNIINLLGACTQDGPLYVIVEYASKGNLREYLQARRPPGLEYCYNPSHNPEEQLSSKDLVSCAYQVARGMEYLASKKCIHRDLAARNVLVTEDNVMKIADFGLARDIHHIDYYKKTTNGRLPVKWMAPEALFDRIYTHQSDVWSFGVLLWEIFTLGGSPYPGVPVEELFKLLKEGHRMDKPSNCTNELYMMMRDCWHAVPSQRPTFKQLVEDLDRIVALTSNQEYLDLSMPLDQYSPSFPDTRSSTCSSGEDSVFSHEPLPEEPCLPRHPAQLANGGLKRR

Select PDB:

Known Drugs:

source: Multi-Sources

(see table)

Target Drug name MOA Phase Status Disease Source
FGFR1 PEMIGATINIB Fibroblast growth factor receptor 1 inhibitor 4 - neoplasm ATC
FGFR1 INFIGRATINIB Fibroblast growth factor receptor inhibitor 4 - neoplasm ATC
FGFR1 ERDAFITINIB Fibroblast growth factor receptor inhibitor 4 - neoplasm ATC
FGFR1 REGORAFENIB Fibroblast growth factor receptor 1 inhibitor 4 - neoplasm ATC
FGFR1 FUTIBATINIB Fibroblast growth factor receptor inhibitor 4 - neoplasm ATC
FGFR1 PAZOPANIB HYDROCHLORIDE Fibroblast growth factor receptor 1 inhibitor 4 - renal cell carcinoma FDA
DailyMed
FGFR1 PAZOPANIB HYDROCHLORIDE Fibroblast growth factor receptor 1 inhibitor 4 - sarcoma DailyMed
FDA
FGFR1 NINTEDANIB ESYLATE Fibroblast growth factor receptor inhibitor 4 - systemic scleroderma DailyMed
FGFR1 NINTEDANIB ESYLATE Fibroblast growth factor receptor inhibitor 4 - idiopathic pulmonary fibrosis DailyMed
FGFR1 REGORAFENIB Fibroblast growth factor receptor 1 inhibitor 4 - colorectal neoplasm EMA
FGFR1 INFIGRATINIB PHOSPHATE Fibroblast growth factor receptor inhibitor 4 - cholangiocarcinoma FDA
FGFR1 PEMIGATINIB Fibroblast growth factor receptor 1 inhibitor 4 - cholangiocarcinoma EMA
FDA
FGFR1 FUTIBATINIB Fibroblast growth factor receptor inhibitor 4 - cholangiocarcinoma FDA
FGFR1 ERDAFITINIB Fibroblast growth factor receptor inhibitor 4 - urothelial carcinoma FDA
DailyMed
FGFR1 REGORAFENIB Fibroblast growth factor receptor 1 inhibitor 3 Recruiting hepatocellular carcinoma ClinicalTrials
FGFR1 REGORAFENIB Fibroblast growth factor receptor 1 inhibitor 3 Terminated hepatocellular carcinoma ClinicalTrials
FGFR1 BRIVANIB Fibroblast growth factor receptor inhibitor 3 Completed hepatocellular carcinoma ClinicalTrials
FGFR1 REGORAFENIB Fibroblast growth factor receptor 1 inhibitor 3 Completed hepatocellular carcinoma ClinicalTrials
FGFR1 ORANTINIB Fibroblast growth factor receptor inhibitor 3 Terminated hepatocellular carcinoma ClinicalTrials
FGFR1 BRIVANIB Fibroblast growth factor receptor inhibitor 3 Terminated hepatocellular carcinoma ClinicalTrials
FGFR1 PAZOPANIB HYDROCHLORIDE Fibroblast growth factor receptor 1 inhibitor 3 Active, not recruiting clear cell renal carcinoma ClinicalTrials
FGFR1 PAZOPANIB Fibroblast growth factor receptor 1 inhibitor 3 Active, not recruiting clear cell renal carcinoma ClinicalTrials
FGFR1 BRIVANIB Fibroblast growth factor receptor inhibitor 3 Completed carcinoma ClinicalTrials
FGFR1 SURUFATINIB Fibroblast growth factor receptor 1 inhibitor 3 - neoplasm ATC
FGFR1 PAZOPANIB Fibroblast growth factor receptor 1 inhibitor 3 - neoplasm ATC

Note: Only show clinically investigational or approved drugs with protein targets.

Protein Tractability:

source: Open Targets
Small molecule
Antibody
PROTAC
Other modalities
Approved Drug
Advanced Clinical
Phase 1 Clinical
Structure with Ligand
High-Quality Ligand
High-Quality Pocket
Med-Quality Pocket
Druggable Family
Approved Drug
Advanced Clinical
Phase 1 Clinical
UniProt loc high conf
GO CC high conf
UniProt loc med conf
UniProt SigP or TMHMM
GO CC med conf
Human Protein Atlas loc
Approved Drug
Advanced Clinical
Phase 1 Clinical
Literature
UniProt Ubiquitination
Database Ubiquitination
Half-life Data
Small Molecule Binder
Approved Drug
Advanced Clinical
Phase 1 Clinical

PTM Intensity:

source: CPTAC

No intensity data of this site,
show all other sites!

FGFR1OP-Ser152
Cancer Intensity
BRCA
COAD 0.939
HGSC
ccRCC -1.252
GBM -0.437
HNSC 0.67
LUAD -0.476
LUSC
non_ccRCC
PDAC 1.403
UCEC -0.846
FGFR1OP-Ser156
Cancer Intensity
BRCA -0.815
COAD -0.267
HGSC -1.304
ccRCC -0.728
GBM 0.231
HNSC 0.665
LUAD 0.607
LUSC 0.425
non_ccRCC -1.483
PDAC 1.671
UCEC 0.998
FGFR1OP-Ser160
Cancer Intensity
BRCA -0.671
COAD -0.452
HGSC -0.484
ccRCC 0.481
GBM 0.139
HNSC 0.685
LUAD 0.104
LUSC 0.415
non_ccRCC -2.409
PDAC 1.162
UCEC 1.028
FGFR1OP-Ser166
Cancer Intensity
BRCA
COAD
HGSC
ccRCC
GBM -0.619
HNSC 1.154
LUAD
LUSC
non_ccRCC
PDAC
UCEC -0.535
FGFR1OP-Ser172
Cancer Intensity
BRCA
COAD -0.707
HGSC 0.707
ccRCC
GBM
HNSC
LUAD
LUSC
non_ccRCC
PDAC
UCEC
FGFR1OP-Ser228
Cancer Intensity
BRCA -0.086
COAD
HGSC 1.827
ccRCC -1.006
GBM 0.49
HNSC
LUAD 0.067
LUSC 0.403
non_ccRCC -1.479
PDAC
UCEC -0.216
FGFR1OP-Ser254
Cancer Intensity
BRCA -0.327
COAD
HGSC
ccRCC 0.351
GBM
HNSC 1.384
LUAD 0.366
LUSC 0.72
non_ccRCC
PDAC -1.459
UCEC -1.035
FGFR1OP-Thr170
Cancer Intensity
BRCA -0.387
COAD -0.749
HGSC 1.136
ccRCC
GBM
HNSC
LUAD
LUSC
non_ccRCC
PDAC
UCEC
FGFR1OP-Thr55
Cancer Intensity
BRCA 0.691
COAD
HGSC
ccRCC 0.041
GBM
HNSC 1.16
LUAD -0.213
LUSC 0.386
non_ccRCC -1.959
PDAC 0.7
UCEC -0.807
FGFR1OP2-Ser141
Cancer Intensity
BRCA
COAD
HGSC
ccRCC
GBM -1.318
HNSC
LUAD -0.233
LUSC 0.721
non_ccRCC
PDAC
UCEC 0.83

PTM-Disease Association:

source: PTMD

No data.

PTM-Drug Perturbation Response:

source: DecryptM

No data.

Function score:

source: funscoR

No data.

Cross Links: